At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
DMMET-01 +1 moredrug
Likely dose
DMMET-01 1050.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of DMMET-01 on Insulin Sensitivity in Naive Type 2 Diabetes Patients by Glucose CLAMP Technique
In Brief
A Phase 2 clinical trial evaluating DMMET-01 and Placebo for Diabetes Type 2. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The aim of this study is to determine the effect of DMMET-01 on insulin sensitivity by Glucose CLAMP technique in Mexican type 2 diabetes patients, after 2 months of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Type 2
CountriesMexico
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
Primary CompletionFeb 2009
First PostedJul 2009
TodayJul 2026
First PostedJul 16, 2009
Enrollment StartJul 1, 2008
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.0 years ago
Interventions
DMMET-01drug
60 days: 30 days; dose 1050.6 mg per day (before dinner)+ 30 days; dose 1050.6 mg twice a day 30 more days (before breakfast ando before dinner)
Placebodrug
60 days: 30 days placebo once a day (before dinner) + 30 days twice a day (before breakfast and before dinner)